Notably, SIAIS178 also degraded clinically relevant BCR-ABL mutations associated with resistance (G250E, V299L, F317L, and F317V) in a dose-dependent manner, provided more durable suppression of CML cell growth than ABL kinase inhibitors. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.